At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Market Closed 04-02 16:00:00 EDT
18.05
+0.66
+3.80%
盘后18.27
+0.22+1.22%
19:51 EDT
High19.31Low16.76Vol1.53M
Open16.79D1 Closing17.39Amplitude14.66%
Mkt Cap881.70MTradable Cap519.28MTotal Shares48.85M
T/O27.84MT/O Rate5.30%Tradable Shares28.77M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  04-02
BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC
Reuters  ·  04-02
Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC
Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule
Reuters  ·  04-02
Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule
Vor Biopharma Is Maintained at Neutral by Wedbush
Dow Jones  ·  03-31
Vor Biopharma Is Maintained at Neutral by Wedbush
Vor Bio price target raised to $15 from $9 at Wedbush
TIPRANKS  ·  03-31
Vor Bio price target raised to $15 from $9 at Wedbush
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
TIPRANKS  ·  03-30
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate
Benzinga  ·  03-30
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate
Vor Biopharma Initiated at Buy by Jefferies
Dow Jones  ·  03-30
Vor Biopharma Initiated at Buy by Jefferies
Vor Biopharma Q4 profit tops estimates on warrant fair value gain
Reuters  ·  03-30
Vor Biopharma Q4 profit tops estimates on warrant fair value gain
Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M
Reuters  ·  03-30
Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M
Vor Bio doses first patient in Phase 3 telitacicept Sjögren’s disease trial
Reuters  ·  03-30
Vor Bio doses first patient in Phase 3 telitacicept Sjögren’s disease trial
Rpt-Vor Biopharma Q4 Net Income USD 1,722.8 Million VS. Ibes Estimate USD -28.9 Million
THOMSON REUTERS  ·  03-30
Rpt-Vor Biopharma Q4 Net Income USD 1,722.8 Million VS. Ibes Estimate USD -28.9 Million
Vor Bio Doses First Patient in Global Phase 3 Upstream Sjd Registrational Trial of Telitacicept in Primary SjÖGren’s Disease
THOMSON REUTERS  ·  03-30
Vor Bio Doses First Patient in Global Phase 3 Upstream Sjd Registrational Trial of Telitacicept in Primary SjÖGren’s Disease
Jefferies Initiates Vor Biopharma at Buy With $50 Price Target
MT Newswires Live  ·  03-30
Jefferies Initiates Vor Biopharma at Buy With $50 Price Target
Vor Biopharma Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $50
THOMSON REUTERS  ·  03-30
Vor Biopharma Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $50
Vor Bio initiated with a Buy at Jefferies
TIPRANKS  ·  03-30
Vor Bio initiated with a Buy at Jefferies
Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
TIPRANKS  ·  03-30
Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters  ·  03-27
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Vor Biopharma Shares Rise 1.5% After $75 Million Private Placement
THOMSON REUTERS  ·  03-27
Vor Biopharma Shares Rise 1.5% After $75 Million Private Placement
Vor Biopharma Announces $75 Million Private Placement
MT Newswires Live  ·  03-27
Vor Biopharma Announces $75 Million Private Placement

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--